Sammy Datwani, PhD
Dr. Sammy S. Datwani is an influential senior executive, entrepreneur, and innovative technology leader with a demonstrated history of developing emergent technologies and commercializing disruptive revolutionary life science tools, analytical instrumentation, and medical device products. Dr. Datwani has over 20 years of executive and leadership experience building teams and developing solutions that allow customers to meet their biotechnology research and commercial objectives in the fields of microfluidics, genomics, proteomics, analytical chemistry, molecular diagnostics, synthetic biology, and cell engineering.
In addition to his recent appointment at AGED Diagnostics Board of Directors, his current and recent roles include Sr. Vice President, R&D – Synthego Corporation, a venture-backed startup democratizing genome engineering. President – SSD Advisors, LLC., a boutique advising firm. Sr. Director, R&D, Principal Scientist at Labcyte Inc., which was acquired by Beckman Coulter Life Sciences (a Danaher company). Board of Directors/ Investor – CombiNATi Inc., which was acquired by Thermo Fisher Scientific. Dr. Datwani is an author and inventor of numerous scientific publications and holder of more than 25 patents and is actively involved with scientific programming at international meetings and conferences. Dr. Datwani received his B.S. (with honors) and Ph.D. in chemical and biomolecular engineering from Johns Hopkins University, Baltimore, MD, and his M.S. in chemical engineering from Columbia University, New York, New York.
Dr. Datwani was inducted to the College of Fellows of the American Institute of Medical and Biological Engineers (AIMBE) for his contributions to leveraging microscale phenomena to enable label-free and high-throughput experimentation, screening, and precision medicine (see https://aimbe.org/college-of-fellows/cof-3029/ ).